Bessemer Group Inc. Acquires 1,551 Shares of Sanofi $SNY

Bessemer Group Inc. increased its holdings in shares of Sanofi (NASDAQ:SNY) by 35.7% in the second quarter, according to its most recent filing with the SEC. The fund owned 5,890 shares of the company’s stock after acquiring an additional 1,551 shares during the period. Bessemer Group Inc.’s holdings in Sanofi were worth $285,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of SNY. Nuveen LLC bought a new stake in shares of Sanofi during the 1st quarter worth approximately $177,831,000. Federated Hermes Inc. lifted its stake in shares of Sanofi by 58.5% during the 1st quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company’s stock worth $218,933,000 after acquiring an additional 1,456,269 shares during the last quarter. OLD Mission Capital LLC bought a new stake in Sanofi during the 1st quarter valued at $48,938,000. Raymond James Financial Inc. raised its position in Sanofi by 15.1% during the 1st quarter. Raymond James Financial Inc. now owns 3,244,027 shares of the company’s stock valued at $179,914,000 after purchasing an additional 425,597 shares in the last quarter. Finally, LPL Financial LLC raised its position in Sanofi by 18.4% during the 1st quarter. LPL Financial LLC now owns 1,520,721 shares of the company’s stock valued at $84,339,000 after purchasing an additional 236,625 shares in the last quarter. 14.04% of the stock is owned by institutional investors.

Sanofi Trading Down 1.0%

Shares of NASDAQ:SNY opened at $50.05 on Tuesday. Sanofi has a 12-month low of $44.62 and a 12-month high of $60.12. The business’s fifty day simple moving average is $48.69 and its 200-day simple moving average is $49.53. The company has a market capitalization of $122.90 billion, a PE ratio of 11.72, a P/E/G ratio of 1.38 and a beta of 0.51. The company has a current ratio of 1.06, a quick ratio of 0.94 and a debt-to-equity ratio of 0.16.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Friday, October 24th. The company reported $1.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.10. The business had revenue of $14.53 billion for the quarter, compared to the consensus estimate of $12.62 billion. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The business’s revenue was down 7.5% compared to the same quarter last year. During the same period last year, the business posted $2.25 EPS. As a group, equities research analysts predict that Sanofi will post 4.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SNY has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft raised Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 2nd. JPMorgan Chase & Co. raised Sanofi from a “neutral” rating to an “overweight” rating in a research report on Friday, August 8th. Morgan Stanley raised Sanofi from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $56.00 to $58.00 in a research report on Monday, September 8th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Sanofi in a research report on Monday, October 27th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Sanofi in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $62.67.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.